+74.3%
DOCN vs MRNA
+896.8%
-822.5%
-61.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +9.6% | -0.9% | +10.4% | +9.6% |
| 7D | +3.7% | -3.8% | +7.5% | +3.7% |
| 30D | -33.7% | +16.4% | -50.0% | -33.6% |
| 3M | -27.9% | +310.6% | -338.5% | -25.2% |
| 6M | -46.4% | +370.3% | -416.7% | -46.3% |
| YTD | +81.1% | +743.3% | -662.2% | +55.7% |
| 1Y | +74.3% | +841.7% | -767.4% | +41.6% |
| All | +74.3% | +896.8% | -822.5% | +41.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling